Following a positive opinion from the European Medicines Agency, the European Commission authorised a fourth Covid-19 vaccine on Thursday 11 March. This is the viral vector vaccine developed by Johnson & Johnson, the first to only require one injection.
In giving its opinion, the European Medicines Agency (EMA) examined the results of a clinical study conducted on 44,000 people, which concluded that the vaccine was 67% effective among symptomatic cases. It felt that the benefits...